Walleye Capital LLC Acquires 67,946 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Walleye Capital LLC grew its holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 446.2% in the 3rd quarter, Holdings Channel reports. The fund owned 83,175 shares of the company’s stock after purchasing an additional 67,946 shares during the quarter. Walleye Capital LLC’s holdings in Prelude Therapeutics were worth $172,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Prelude Therapeutics by 1.0% in the first quarter. Vanguard Group Inc. now owns 1,016,999 shares of the company’s stock valued at $4,821,000 after acquiring an additional 10,143 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Prelude Therapeutics by 2.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company’s stock worth $1,990,000 after purchasing an additional 14,226 shares during the period. Dimensional Fund Advisors LP lifted its position in Prelude Therapeutics by 103.2% in the second quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock worth $111,000 after purchasing an additional 14,769 shares during the period. Finally, Exchange Traded Concepts LLC lifted its position in Prelude Therapeutics by 32.2% in the third quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock worth $133,000 after purchasing an additional 15,682 shares during the period. 79.72% of the stock is owned by institutional investors.

Prelude Therapeutics Price Performance

Prelude Therapeutics stock opened at $0.94 on Thursday. The stock has a fifty day moving average price of $1.38 and a two-hundred day moving average price of $3.32. Prelude Therapeutics Incorporated has a 52-week low of $0.91 and a 52-week high of $6.80. The firm has a market capitalization of $51.73 million, a P/E ratio of -0.54 and a beta of 1.49.

Prelude Therapeutics (NASDAQ:PRLD) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. The company had revenue of $3.00 million for the quarter. On average, equities research analysts predict that Prelude Therapeutics Incorporated will post -1.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on PRLD shares. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Prelude Therapeutics in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.